When pharmaceutical organizations select software to support GxP-regulated operations, one of the most important considerations is how well the system can meet business requirements without requiring custom software development. The distinction between a configured solution and a customized solution can have a significant impact not only on implementation time and long-term maintainability, but also on the effort, documentation, testing, and risk associated with computer system validation (CSV).
The International Society for Pharmaceutical Engineering (ISPE) GAMP 5 (Good Automated Manufacturing Practice) framework provides a risk-based approach for implementing and maintaining computerized systems in regulated and controlled environments. Within the traditional GAMP software categorization model, configured products are generally assigned a status of “Category 4”. Applications that are homegrown or off-the-shelf that require modified or new custom code are assigned a status of “Category 5”.
Understanding the differences between these two categories can help pharmaceutical organizations make informed decisions about how they select, design, implement, validate, and maintain their enterprise systems.
What Is a GAMP 5 Category 4 Configured Solution?
A Category 4 solution is generally a commercially available software product that can be configured using the system’s user interface (UI) to meet an organization's specific business processes without modifying or creating new underlying application source code.
Configuration allows an organization to tailor the behavior of an existing product using existing and system-based functionality that has already been designed into the application. Depending on the system, this may include:
- User-defined workflows and approval processes
- User roles and security permissions
- Electronic signature requirements
- Business rules and system parameters
- User-defined fields and screens
- Reports and dashboards
- Material, product, warehouse, and location structures
- Quality and status controls
- Transaction rules and approval thresholds
The key distinction is that these capabilities exist within the established framework of the commercial product. The customer or the solution vendor’s administrators are configuring the system rather than developing new or modifying existing application code.
For example, a pharmaceutical ERP platform may provide a configurable workflow engine. One customer might configure a material release process requiring Quality Assurance approval before inventory can become available, while another customer may require both Quality Assurance and Operations approval.
Although the workflows differ, both organizations are using functionality already provided by the software product. From the system’s perspective, it may be as easy as checking a box to change the functionality.
What Is a GAMP 5 Category 5 Customized Solution?
Category 5 generally refers to custom applications or custom-developed software components added to existing systems that are designed and coded to satisfy specific user or business requirements.
Instead of selecting options or defining behavior through existing configuration tools, developers may need to write or modify software code.
Examples can include:
- Homegrown applications created from scratch
- Writing custom application modules
- Modifying core application source code
- Creating unique functionality that does not exist within the commercial “off the shelf” product
- Developing custom algorithms or processing logic
- Building interfaces or components through software development
This distinction is important because custom code introduces additional variables (like, most importantly, risk) that must be understood and controlled.
With configuration, an organization is generally using functionality that has already been developed and tested as part of their standardized software development lifecycle (SDLC). With customization, new software behavior is being created specifically for the organization. By introducing new code and not testing the functionality to a satisfactory level, the level of risk to the system and the business is enhanced.
GAMP 5 Category 4 vs. Category 5: Key Differences
Read Also: FDA Computer System Validation Documentation: IQ, OQ, PQ & 21 CFR Part 11 Guide
How GAMP 5 Category 4 and Category 5 Affect Validation
Both configured and customized GxP systems must be demonstrated to be fit for their intended use. Category 4 does not mean that validation is unnecessary. Alternatively, Category 5 does not automatically mean that a system is unsuitable for a regulated environment.
The difference is primarily in the risk, complexity, supplier evidence, and validation activities necessary to establish confidence in the system.
A configured commercial product may already have significant development controls, product testing, release management, and documentation provided by the software supplier. A regulated customer can evaluate the supplier and determine what supplier documentation and testing can appropriately be leveraged as part of its validation strategy.
The customer can then focus its validation effort on its intended use, critical business processes, configured functionality, interfaces, data integrity controls, and other areas presenting meaningful GxP risk.
This is consistent with the GAMP 5 philosophy of applying a science- and risk-based approach rather than treating every function and every system as requiring identical levels of testing.
Category 5 Typically Requires Greater Development Assurance
Customized software generally requires additional attention because the organization must establish confidence not only in how the system has been implemented, but also in the newly developed software itself.
Depending on the nature and risk of the customization, additional lifecycle documentation and evidence may include:
- Detailed functional and design specifications
- Software development lifecycle documentation
- Code review evidence
- Unit and integration testing
- Traceability between requirements, specifications, and testing
- Defect and remediation records
- Additional regression testing
- Change control documentation
The extent of these activities should be based on risk. A custom component supporting a critical calculation or product-release decision, for example, may warrant substantially greater assurance than a low-risk function with no impact on product quality or patient safety.
The practical result is that Category 5 functionality can increase both the initial validation burden and the ongoing effort required to maintain the system's validated state.
The Impact Continues After Go-Live
The difference between configuration and customization becomes especially important when software is upgraded.
With a configured commercial solution, configuration is generally maintained within the application's supported framework. When the software vendor releases an update, the organization can perform a risk assessment to determine which GxP-critical functions and configured processes may be affected and what regression testing is appropriate.
Custom-developed functionality may require additional analysis.
An upgrade to the underlying commercial application could affect custom code, integrations, or dependencies. Organizations may need to determine whether customized components remain compatible, whether code changes are necessary, and whether additional development and regression testing are required.
Over the life of an ERP or other enterprise platform, these differences can significantly affect the total cost of validation and system ownership.
Read Also: OQ Scripts and FRS Templates for 21 CFR Part 11 Software: How to Validate Your Pharma ERP
Configuration Does Not Automatically Mean Lower Risk
It is important not to interpret GAMP categories as simple risk rankings.
A Category 4 system can support highly critical GxP processes. For example, a configured ERP may control lot status, expiration dates, material release, electronic signatures, inventory transactions, or other functions that directly affect regulated operations.
Those processes still require appropriate validation.
Similarly, simply calling something "configuration" does not determine the appropriate validation approach. Organizations should evaluate what the configured functionality actually does, how it was implemented, the potential impact of failure, and what evidence is necessary to demonstrate that it performs as intended.
The objective is not to minimize documentation simply because a solution is configurable. The objective is to apply validation effort where it provides the greatest assurance and value.
Why Pharma-Focused Configurability Matters
For pharmaceutical companies, one advantage of selecting a purpose-built configurable platform is that many industry-specific requirements can potentially be addressed through existing product functionality rather than custom development.
A pharma-focused ERP, for example, may already provide functionality for:
- Lot and batch traceability
- Material status and quarantine controls
- Quality approval workflows
- Electronic signatures and audit trails
- Expiration and retest dates
- Inventory genealogy
- Manufacturing and packaging processes
- Supplier and contract manufacturer interactions
- Role-based security
- GxP recordkeeping and data integrity controls
When these capabilities are inherent to the product and can be configured to the customer's processes, organizations may be able to reduce their dependence on custom software development.
This can simplify both implementation and ongoing validation.
The Slingshot Pharma Approach
Slingshot Pharma is designed as a configurable, pharma-focused ERP platform, allowing organizations to adapt the solution to their specific operational requirements while minimizing the need for traditional custom development.
This approach is particularly valuable in regulated environments because pharmaceutical organizations rarely operate exactly the same way. Approval workflows, organizational structures, manufacturing processes, material controls, and business rules can vary significantly between companies.
Rather than requiring customers to modify the underlying application code for every difference, a configurable platform allows many of these requirements to be addressed within the established functionality of the solution.
From a validation perspective, this can provide an important advantage. Organizations can focus their validation strategy on their intended use, configured business processes, GxP-critical functionality, integrations, and identified risks, while leveraging appropriate supplier documentation and testing where justified.
The result is not the elimination of validation. GxP systems must still be appropriately validated for their intended use.
Instead, the objective is to reduce unnecessary custom development and concentrate validation effort on the functionality and processes that matter most to product quality, patient safety, and data integrity.
Read Also: Best ERP Software for Pharmaceutical Manufacturing: Expert Guide to Choose the Best Software
Conclusion
The distinction between GAMP 5 Category 4 configured solutions and Category 5 customized solutions is more than a technical classification. It can influence the entire lifecycle of a regulated computerized system.
Configured solutions use established product functionality that is tailored to an organization's requirements, while customized solutions introduce newly developed software or functionality. Both can be successfully validated, but custom development generally introduces additional development assurance, documentation, testing, change-control, and regression-testing considerations.
For pharmaceutical organizations evaluating ERP and other GxP systems, the question should therefore not simply be, "Can this system meet our requirements?"
An equally important question is:
"Can the solution meet our business processes through configuration? Will we need to develop and maintain custom software to do it?"
Choosing a solution designed to accommodate pharmaceutical requirements through configuration can help organizations implement systems that meet their operational needs while supporting a more focused, risk-based, and sustainable validation strategy throughout the system lifecycle.
.png)